Abstract:Background: Patients with atopic dermatitis (AD) exhibit heterogeneous clinical phenotypes, reflecting different combinations of itch and lesional severity. AD with severe itch but clear-moderate lesions, also known as itch-dominant AD, is a common clinical phenotype. Objectives: To evaluate abrocitinib efficacy in patients with moderate-to-severe AD who have itch-dominant AD. Methods: This post hoc analysis includes pooled data from clinical trials of patients with moderate-to-severe AD receiving abrocitinib (100 or 200 mg) as monotherapy (phase 2b; phase 3 JADE MONO-1 and JADE MONO-2) or in combination with topical therapy (phase 3 JADE COMPARE). Data from the ongoing long-term JADE EXTEND trial (data cutoff April 2020) were also evaluated. Itch-dominant AD was defined as baseline Peak Pruritus Numerical Rating Scale (PP-NRS) score of 7-10 and Investigator's Global Assessment of 0-3 or Eczema Area and Severity Index of 0‒21. Assessments included a ≥4-point improvement in PP-NRS (PP-NRS4), PP-NRS score of 0 (no itch) or 1 (little itch) in patients with PP-NRS score ≥2 at baseline, ≥4-point improvement from baseline in Patient-Oriented Eczema Measure (POEM-4), Patient Global Assessment (PtGA) of clear or almost clear, and Dermatology Life Quality Index (DLQI) score of 0 or 1 (no impact or little impact of AD on quality of life [QoL]). Results: In the pooled monotherapy trials, 37% of patients had itch-dominant AD at baseline. As early as Week 2, more patients with itch-dominant AD achieved PP-NRS4 with abrocitinib 100 mg (35%) and abrocitinib 200 mg (57%) versus placebo (7%); 6% and 22% versus 0%, respectively, achieved PP-NRS 0/1. More patients achieved a PtGA of clear/almost clear at Week 12 with abrocitinib 100 mg (28%) and abrocitinib 200 mg (45%) than placebo (9%). Additionally, abrocitinib led to clinically meaningful improvements in POEM and DLQI. Most patients with itch-dominant AD experienced itch improvement over time with abrocitinib monotherapy or with concomitant topical therapy; 86%-87% and 62%-67% of patients had no itch-moderate itch and clear-moderate lesions by weeks 24 and 48, respectively. Conclusions: Abrocitinib is highly efficacious in patients with itch-dominant AD, demonstrating rapid, deep, and sustained improvements in itch and clinically meaningful improvements in patients' QoL. Trial registration numbers: NCT02780167; NCT03349060; NCT03575871; NCT03720470; NCT03422822.

Adjunctive Management of Itch in Atopic Dermatitis

Update on the Pathogenesis and Therapy of Atopic Dermatitis

Integrative Treatment Approaches with Mind–Body Therapies in the Management of Atopic Dermatitis

Atopic dermatitis: a brief review of recent advances in management

Atopic Dermatitis Itch: Scratching for an Explanation

Atopic dermatitis: treatment and innovations in immunotherapy

Abrocitinib may improve itch and quality of life in patients with itch-dominant atopic dermatitis

An Altered Skin and Gut Microbiota Are Involved in the Modulation of Itch in Atopic Dermatitis

Updates in atopic dermatitis for the primary care physician: A review of advances in the understanding and treatment of atopic dermatitis

Itch Management: Systemic Agents

Therapeutic management of atopic dermatitis

Novel Topical Treatments for Itch

Insights into Early Systemic Treatment in Atopic Dermatitis: Scientific Facts and Practical Considerations

Integrative Medicine as Adjunct Therapy in the Treatment of Atopic Dermatitis—the Role of Traditional Chinese Medicine, Dietary Supplements, and Other Modalities

Atopic Dermatitis: Managing the Itch

Advancements in Allergen Immunotherapy for the Treatment of Atopic Dermatitis

Exploring the Complexities of Atopic Dermatitis: Pathophysiological Mechanisms and Therapeutic Approaches

Recent Advancements in the Atopic Dermatitis Mechanism

Molecular and cellular mechanisms of itch and pain in atopic dermatitis and implications for novel therapeutics

Cutaneous Components Leading to Pruritus, Pain, and Neurosensitivity in Atopic Dermatitis: A Narrative Review

Atopic dermatitis: pathomechanisms and lessons learned from novel systemic therapeutic options